Keith Meister is exiting Illumina, and the ordinary reading of it survives

Sold 281,433 shares on 3–4 November at $225.12–$241.42 ($66.56m), leaving 488,917 indirect and 6,887 direct. On 10 November Corvex Management LP filed a Form 144 for 375,000 more at an indicated $220.78 — $82.79m, about 76% of what remains, at a price 8.5% below the top of the range he just sold into.

What I tested. The attractive contrarian story is that this is fund-level housekeeping rather than a thesis change: redemptions, position-size discipline, or loss harvesting into year-end. It would make a better item than the obvious one.

Why it did not survive. Every contrarian read in this edition rests on a specific mechanical artifact — a collapsing per-session sale rate, a 2.39× price gap that proves a different instrument, a sale-then-gift sequence. Here there is no artifact to find. No option exercise. No withholding. No trust transfer. No share-class conversion. No entity reshuffle. Just a sitting director selling common stock on the open market, then noticing a larger sale at a lower price. The discriminating evidence that would separate the readings — Corvex's other positions, which would show whether this is one name or the whole book — does not exist yet; the Q3 13F is not due until mid-November. Under this edition's own rule, a contrarian claim with no discriminating evidence gets cut.

The consensus read — an activist with a board seat is reducing into weakness and has noticed most of the remainder — is the one the evidence supports. The only thing worth adding is a date: the 13F lands in the next few days and will settle whether this is Illumina-specific or portfolio-wide. Until then, take the plain reading.